AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7143011 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproheptadine (6 mg to 24 mg per day)
Number of subjects: 6
Study 31328281 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-focused cognitive behavioral treatment (F-CBT)
Number of subjects: 147
Study 31328281 — intervention group
Group type: COMPARATOR
Intervention: Enhanced treatment-as-usual (E-TAU)
Number of subjects: 147
Study 28894075 — intervention group
Group type: EXPERIMENTAL
Intervention: Dongchimi juice
Number of subjects: 32
Study 28894075 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine solution (0.12% dilution)
Number of subjects: 32
Study 27471390 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed intermittent epidural bolus (IEB)
Number of subjects: 200
Study 27471390 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural infusion (CEI)
Number of subjects: 200
Study 23639779 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (FCM)
Number of subjects: 415
Study 23639779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 415
Study 20724740 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm resistance training, 3 times a week for 6 weeks
Number of subjects: 36
Study 20724740 — intervention group
Group type: COMPARATOR
Intervention: Sham control, 3 times a week for 6 weeks
Number of subjects: 36
Study 19735563 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Therapy exclusively with standardized protocols
Number of subjects: 62
Study 19735563 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder Dynasplint system exclusively
Number of subjects: 62
Study 19735563 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with Shoulder Dynasplint and standardized Physical Therapy
Number of subjects: 62
Study 19735563 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group I)
Number of subjects: 62
Study 17283299 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including office-based expert system assessment, brief stage-based counseling, expert system-generated feedback reports, printed manual, and mailed tip sheets.
Number of subjects: 819
Study 17283299 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention as described above.
Number of subjects: 819
Study 17283299 — intervention group
Group type: COMPARATOR
Intervention: Control group received a physical activity and nutrition intervention.
Number of subjects: 819
Study 17283299 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion of more intervention sessions.
Number of subjects: 819
Study 15209578 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1000 mg PO 1 hour before cath/PCI and 4 hours later
Number of subjects: 80
Study 15209578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 15209578 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 80
Study 11755455 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 300 microg of CNP
Number of subjects: 20
Study 11755455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9520616 — intervention group
Group type: EXPERIMENTAL
Intervention: Methimazole treatment for 11.2 ± 1.0 weeks
Number of subjects: 12
Study 7975860 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma-derived vaccine (Hevac B)
Number of subjects: 50
Study 7975860 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant HBsAg vaccine (Engerix-B)
Number of subjects: 50
Study 7975860 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 50
Study 3132383 — intervention group
Group type: EXPERIMENTAL
Intervention: roxithromycin (150 mg 2 X day)
Number of subjects: 160
Study 3132383 — intervention group
Group type: COMPARATOR
Intervention: cephradine (1.0 g 2 X day)
Number of subjects: 160
Study 31924662 — intervention group
Group type: EXPERIMENTAL
Intervention: BLT+MLT+MP
Number of subjects: 67
Study 31924662 — intervention group
Group type: EXPERIMENTAL
Intervention: BLT+placebo of MLT+placebo of MP
Number of subjects: 67
Study 31924662 — intervention group
Group type: EXPERIMENTAL
Intervention: BLT
Number of subjects: 67
Study 31924662 — intervention group
Group type: EXPERIMENTAL
Intervention: MLT
Number of subjects: 67
Study 31924662 — intervention group
Group type: EXPERIMENTAL
Intervention: MP
Number of subjects: 67
Study 31924662 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo for BLT, MLT and MP)
Number of subjects: 67
Study 31230261 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg/day
Number of subjects: 336
Study 31230261 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg/day
Number of subjects: 336
Study 31230261 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg + Aspirin 100 mg
Number of subjects: 336
Study 31230261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 336
Study 28463849 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat (40 mg thrice weekly)
Number of subjects: 57
Study 28463849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 25416737 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror therapy-based action observation (AO) group
Number of subjects: 37
Study 25416737 — intervention group
Group type: COMPARATOR
Intervention: Control observation (CO) group
Number of subjects: 37
Study 25416737 — intervention group
Group type: COMPARATOR
Intervention: Comparison between AO and CO groups
Number of subjects: 37
Study 23353589 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia followed by intravenous morphine analgesia (Group A)
Number of subjects: 56
Study 23353589 — intervention group
Group type: COMPARATOR
Intervention: Epidural anesthesia followed by epidural analgesia (Group B)
Number of subjects: 56
Study 21533031 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination ART
Number of subjects: 96
Study 18280129 — intervention group
Group type: EXPERIMENTAL
Intervention: Stair-climbing
Number of subjects: 16
Study 18280129 — intervention group
Group type: COMPARATOR
Intervention: Walking
Number of subjects: 16
Study 16483745 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (initiated at 15 mg/d, adjusted between 10-30 mg/d)
Number of subjects: 1599
Study 16483745 — intervention group
Group type: COMPARATOR
Intervention: Safety Control (another antipsychotic medication, dosed according to prescribing guidelines)
Number of subjects: 1599
Study 14512669 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportional Assist Ventilation (PAV)
Number of subjects: 9
Study 14512669 — intervention group
Group type: COMPARATOR
Intervention: Pressure Support Ventilation (PSV)
Number of subjects: 9
Study 10856385 — intervention group
Group type: EXPERIMENTAL
Intervention: bFGF (basic fibroblast growth factor) 30 to 100 microg/kg
Number of subjects: 25
Study 10856385 — intervention group
Group type: EXPERIMENTAL
Intervention: bFGF (basic fibroblast growth factor) 3 to 30 microg/kg
Number of subjects: 25
Study 10856385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 9165611 — intervention group
Group type: EXPERIMENTAL
Intervention: Alarm plus 40 micrograms desmopressin (Minirin, DDAVP) nasal spray
Number of subjects: 71
Study 9165611 — intervention group
Group type: COMPARATOR
Intervention: Alarm monotherapy
Number of subjects: 71
Study 1489500 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine collagen membrane dressing
Number of subjects: 2
Study 1489500 — intervention group
Group type: COMPARATOR
Intervention: Petroleum jelly gauze dressing
Number of subjects: 2
Study 4085353 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal
Number of subjects: 7
Study 4085353 — intervention group
Group type: COMPARATOR
Intervention: Water alone
Number of subjects: 7
Study 29767638 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/FTC (Tenofovir Disoproxil Fumarate/Emtricitabine)
Number of subjects: 200
Study 29767638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 27163250 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile upper extremity rehabilitation program (MoU-Rehab) combined with conventional occupational therapy (OT)
Number of subjects: 24
Study 27163250 — intervention group
Group type: COMPARATOR
Intervention: Conventional occupational therapy (OT) alone
Number of subjects: 24
Study 25339206 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (AET)
Number of subjects: 57
Study 25339206 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 57
Study 25339206 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 57
Study 22815078 — intervention group
Group type: EXPERIMENTAL
Intervention: STAM‐Dem protocol (2 weekly sessions of 45 minutes for 12 weeks)
Number of subjects: 51
Study 22815078 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 51
Study 20133918 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 mg/kg IV tissue plasminogen activator within 3 hours of symptom onset
Number of subjects: 113
Study 17853158 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg sublingual misoprostol 2 hours prior to the procedure
Number of subjects: 72
Study 17853158 — intervention group
Group type: COMPARATOR
Intervention: 400 microg vaginal misoprostol 3 hours prior to the procedure
Number of subjects: 72
Study 16225494 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin 40 microg/30 min
Number of subjects: 6
Study 12160332 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF)
Number of subjects: 30
Study 12160332 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion (saline)
Number of subjects: 30
Study 10480442 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 0
Study 8647514 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with newly diagnosed chronic lymphoid malignancies
Number of subjects: 59
Study 8647514 — intervention group
Group type: COMPARATOR
Intervention: Patients with localized disease
Number of subjects: 59
Study 8647514 — intervention group
Group type: EXPERIMENTAL
Intervention: High-grade non-Hodgkin's lymphoma
Number of subjects: 59
Study 8647514 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium levels
Number of subjects: 59
Study 2282940 — intervention group
Group type: EXPERIMENTAL
Intervention: Krypton laser treatment
Number of subjects: 91
Study 2282940 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser treatment
Number of subjects: 91
Study 7308950 — intervention group
Group type: EXPERIMENTAL
Intervention: Unclamped umbilical cord
Number of subjects: 414
Study 7308950 — intervention group
Group type: COMPARATOR
Intervention: Clamped umbilical cord
Number of subjects: 414
Study 31227019 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (400 μg administered sublingually every 3 hours up to five doses within 24 hours)
Number of subjects: 1192
Study 31227019 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1192
Study 28513179 — intervention group
Group type: EXPERIMENTAL
Intervention: Watermelon juice enriched with l-Citrulline and pomegranate ellagitannins
Number of subjects: 19
Study 25655899 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg once daily
Number of subjects: 17
Study 25655899 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 25655899 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 17
Study 24101149 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulation (OAC) discontinued after successful AF ablation; average 7.3 months follow-up off OAC.
Number of subjects: 108
Study 24101149 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients remaining on OAC post-ablation; 32/37 (86.5%) of patients with AF post-ablation remained on OAC.
Number of subjects: 108
Study 24101149 — intervention group
Group type: COMPARATOR
Intervention: Patients off OAC; 0% bleeding risk reported.
Number of subjects: 108
Study 24101149 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients AF free post-ablation; 71 patients (65.7%) were AF free 2.8 years after last ablation.
Number of subjects: 108
Study 21854674 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Rhino
Number of subjects: 30
Study 21854674 — intervention group
Group type: COMPARATOR
Intervention: Merocel
Number of subjects: 30
Study 18583993 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooled BSS Plus at 10 degrees C
Number of subjects: 70
Study 18583993 — intervention group
Group type: COMPARATOR
Intervention: Room temperature BSS Plus at 23 degrees C
Number of subjects: 70
Study 17668977 — intervention group
Group type: EXPERIMENTAL
Intervention: MM + SRP
Number of subjects: 127
Study 17668977 — intervention group
Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 127
Study 15350316 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening examination including IOP measurement, CCT, slit-lamp examination, fundus photography, and visual field test.
Number of subjects: 3021
Study 15350316 — intervention group
Group type: EXPERIMENTAL
Intervention: POAG with IOP levels of 21 mmHg or less.
Number of subjects: 3021
Study 15350316 — intervention group
Group type: EXPERIMENTAL
Intervention: POAG with IOP levels of more than 21 mmHg.
Number of subjects: 3021
Study 15350316 — intervention group
Group type: EXPERIMENTAL
Intervention: Average IOP for eyes with POAG (right eye).
Number of subjects: 3021
Study 15350316 — intervention group
Group type: EXPERIMENTAL
Intervention: Average IOP for eyes with POAG (left eye).
Number of subjects: 3021
Study 15350316 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean CCT of POAG eyes with IOP levels of 21 mmHg or less (right eye).
Number of subjects: 3021
Study 15350316 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean CCT of POAG eyes with IOP levels of 21 mmHg or less (left eye).
Number of subjects: 3021
Study 12217084 — intervention group
Group type: EXPERIMENTAL
Intervention: T(LBE)
Number of subjects: 12
Study 12217084 — intervention group
Group type: EXPERIMENTAL
Intervention: T(UBE)
Number of subjects: 12
Study 12217084 — intervention group
Group type: EXPERIMENTAL
Intervention: T(UBE) and T(LBE)
Number of subjects: 12
Study 9624641 — intervention group
Group type: EXPERIMENTAL
Intervention: High Glycemic Index (HGI)
Number of subjects: 8
Study 9624641 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Glycemic Index (LGI)
Number of subjects: 8
Study 9624641 — intervention group
Group type: COMPARATOR
Intervention: Placebo (CON)
Number of subjects: 8
Study 7660345 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult bronchoscope
Number of subjects: 20
Study 7660345 — intervention group
Group type: EXPERIMENTAL
Intervention: Paediatric bronchoscope
Number of subjects: 20
Study 2651016 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine (max. 20 mg/day)
Number of subjects: 30
Study 2651016 — intervention group
Group type: COMPARATOR
Intervention: Baclofen (max. 50 mg/day)
Number of subjects: 30
Study 2651016 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine
Number of subjects: 30
Study 2651016 — intervention group
Group type: COMPARATOR
Intervention: Baclofen
Number of subjects: 30
Study 340132 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole (2 g once daily for 3 days)
Number of subjects: 56
Study 340132 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole (2 g once daily for 3 days)
Number of subjects: 56
Study 31941864 — intervention group
Group type: EXPERIMENTAL
Intervention: Blueberry leaves (BL) beverage
Number of subjects: 0
Study 31941864 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 0
Study 31109201 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray (56 or 84 mg twice weekly) plus newly initiated antidepressant
Number of subjects: 227
Study 31109201 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant plus placebo nasal spray
Number of subjects: 227
Study 31109201 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray plus antidepressant
Number of subjects: 227
Study 28370745 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable diaper products
Number of subjects: 0
Study 28370745 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult incontinence products
Number of subjects: 0
Study 26444879 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation
Number of subjects: 374
Study 26444879 — intervention group
Group type: COMPARATOR
Intervention: Oxygen therapy
Number of subjects: 374
Study 24103587 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate dialysis fluid (1 mM citrate, 1.5 mM calcium)
Number of subjects: 20
Study 24103587 — intervention group
Group type: COMPARATOR
Intervention: Control fluid (3 mM acetate, 1.5 mM calcium)
Number of subjects: 20
Study 21311345 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent training (CG)
Number of subjects: 23
Study 21311345 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (EG)
Number of subjects: 23
Study 21311345 — intervention group
Group type: COMPARATOR
Intervention: Strength training (SG)
Number of subjects: 23
Study 19685935 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotonic PEG (12 g once or twice daily or once every other day for 4 weeks)
Number of subjects: 62
Study 19685935 — intervention group
Group type: COMPARATOR
Intervention: Isotonic PEG (12 g once or twice daily or once every other day for 4 weeks)
Number of subjects: 62
Study 19685935 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotonic PEG
Number of subjects: 62
Study 19685935 — intervention group
Group type: COMPARATOR
Intervention: Isotonic PEG
Number of subjects: 62
Study 17074112 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate, 10 mg/d
Number of subjects: 185
Study 17074112 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone, 1.25 mg/d
Number of subjects: 185
Study 17074112 — intervention group
Group type: COMPARATOR
Intervention: Calcium preparation only
Number of subjects: 185
Study 15330687 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline
Number of subjects: 419
Study 15330687 — intervention group
Group type: COMPARATOR
Intervention: Levodopa
Number of subjects: 419
Study 11587703 — intervention group
Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation (ORIF)
Number of subjects: 52
Study 11587703 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 52
Study 9024732 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g/day supplemental water‐soluble dietary fiber (WSDF; a mixture of psyllium, pectin, guar gum, and locust bean gum)
Number of subjects: 51
Study 9024732 — intervention group
Group type: COMPARATOR
Intervention: Inactive WSDF control (acacia gum)
Number of subjects: 51
Study 8388352 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparins administered subcutaneously
Number of subjects: 0
Study 3326044 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam 2 x 3g
Number of subjects: 39
Study 3326044 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam 2 x 12g
Number of subjects: 39
Study 3326044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 29890086 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (3× weekly) with standardized tobramycin inhalation solution (TIS)
Number of subjects: 221
Study 29890086 — intervention group
Group type: COMPARATOR
Intervention: Placebo with standardized tobramycin inhalation solution (TIS)
Number of subjects: 221
Study 27607859 — intervention group
Group type: EXPERIMENTAL
Intervention: Quickstart group (depot medroxyprogesterone acetate with mifepristone)
Number of subjects: 461
Study 27607859 — intervention group
Group type: COMPARATOR
Intervention: Afterstart group (depot medroxyprogesterone acetate after abortion)
Number of subjects: 461
Study 27607859 — intervention group
Group type: EXPERIMENTAL
Intervention: Quickstart group
Number of subjects: 461
Study 27607859 — intervention group
Group type: COMPARATOR
Intervention: Afterstart group
Number of subjects: 461
Study 25333437 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial coating on scrubs
Number of subjects: 0
Study 25333437 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antimicrobial coating)
Number of subjects: 0
Study 23419913 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal physical therapies
Number of subjects: 181
Study 21170106 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil cream 500 μg
Number of subjects: 400
Study 21170106 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil cream 700 μg
Number of subjects: 400
Study 21170106 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil cream 900 μg
Number of subjects: 400
Study 21170106 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 400
Study 18668406 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 hr sampling duration
Number of subjects: 138
Study 18668406 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 hr sampling duration
Number of subjects: 138
Study 18668406 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 hr or less sampling duration
Number of subjects: 138
Study 18668406 — intervention group
Group type: COMPARATOR
Intervention: Full-shift measurements
Number of subjects: 138
Study 16167268 — intervention group
Group type: EXPERIMENTAL
Intervention: Boxers
Number of subjects: 11
Study 16167268 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 11
Study 12511361 — intervention group
Group type: EXPERIMENTAL
Intervention: Artisan toric phakic intraocular lenses (TPIOLs) implantation
Number of subjects: 53
Study 11334057 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐rHuMGDF at a dose of 5.0 microg/kg/day
Number of subjects: 43
Study 11334057 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐rHuMGDF
Number of subjects: 43
Study 8803380 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl citrate, hydromorphone hydrochloride, methadone hydrochloride, and morphine sulfate solutions
Number of subjects: 0
Study 8803380 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin sodium
Number of subjects: 0
Study 1536216 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-nonstress test
Number of subjects: 60
Study 1536216 — intervention group
Group type: COMPARATOR
Intervention: Assisted nonstress test
Number of subjects: 60